Glaukos News
Print this Article | Send to Colleague
Glaukos News
You Might Be Surprised by the Attitudes and Behaviors of your Glaucoma Patients
Glaukos convened a panel of glaucoma experts to discuss the recently published “Interventional glaucoma consensus treatment protocol”. These experts have all implemented the consensus protocol in their clinics and have been surprised by some of the repercussions on their practice and their patients.
Every optometrist knows the daily grind of managing glaucoma patients on multiple topical medications: endless refill calls, callbacks for red-eye complaints, adherence counseling that rarely sticks, and back-of-house staff hours that never make it onto a claim form. With the invention of Micro Invasive Glaucoma Surgery (MIGS) and the evolution of interventional glaucoma therapy, we now have options for improving compliance and long-term IOP control with significantly fewer side-effects and less administrative burden on the optometric clinic.
In this fast-paced video roundtable, four leading ophthalmic surgeons explain why they now favor MIGS and procedural pharmaceuticals over lifelong drop therapy. Their focus is patient-centric—better comfort, fewer side effects, superior adherence—but the unspoken win is for the optometrists who manage the long-term health of their glaucoma patients: fewer emergency slots, less unbillable chair time, and a smoother front desk workflow.
Spend eleven minutes with these experts and learn how interventional glaucoma therapy is viewed by patients on drops, and how MIGS and procedural pharmaceuticals impact patient adherence to prescribed follow-up care.
